Are Opioids Needed to Treat Chronic Low Back Pain? A Review of Treatment Options and Analgesics in Development

被引:12
作者
Gudin, Jeffrey [1 ,2 ]
Kaufman, Andrew G. [1 ]
Datta, Samyadev [1 ,3 ]
机构
[1] Rutgers New Jersey Med Sch, Dept Anesthesiol, Newark, NJ USA
[2] Englewood Hosp & Med Ctr, Dept Anesthesiol, Englewood, NJ 07631 USA
[3] Ctr Pain Management, Hackensack, NJ USA
关键词
non-pharmacologic; opioid; chronic low back pain; analgesia; LOW-DOSE NALTREXONE; BUPRENORPHINE TRANSDERMAL SYSTEM; OXYMORPHONE EXTENDED-RELEASE; TRAMADOL/ACETAMINOPHEN COMBINATION TABLETS; EPIDURAL STEROID INJECTIONS; PLACEBO-CONTROLLED TRIAL; CHRONIC NONCANCER PAIN; CONTROLLED PHASE-III; DOUBLE-BLIND; CDC GUIDELINE;
D O I
10.2147/JPR.S226483
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The continued prevalence of chronic low back pain (CLBP) is a testament to our lack of understanding of the potential causes, leading to significant treatment challenges. CLBP is the leading cause of years lived with disability and the fifth leading cause of disability-adjusted life-years. No single non-pharmacologic, pharmacologic, or interventional therapy has proven effective as treatment for the majority of patients with CLBP. Although non-pharmacologic therapies are generally helpful, they are often ineffective as monotherapy and many patients lack adequate access to these treatments. Noninvasive treatment measures supported by evidence include physical and chiropractic therapy, yoga, acupuncture, and non-opioid and opioid pharmacologic therapy; data suggest a moderate benefit, at most, for any of these therapies. Until our understanding of the pathophysiology and treatment of CLBP advances, clinicians must continue to utilize rational multimodal treatment protocols. Recent Centers for Disease Control and Prevention guidelines for opioid prescribing recommend that opioids not be utilized as first-line therapy and to limit the doses when possible for fear of bothersome or dangerous adverse effects. In combination with the current opioid crisis, this has caused providers to minimize or eliminate opioid therapy when treating patients with chronic pain, leaving many patients suffering despite optimal nonopioid therapies. Therefore, there remains an unmet need for effective and tolerable opioid receptor agonists for the treatment of CLBP with improved safety properties over legacy opioids. There are several such agents in development, including opioids and other agents with novel mechanisms of action. This review critiques non-pharmacologic and pharmacologic treatment modalities for CLBP and examines the potential of novel opioids and other analgesics that may be a useful addition to the treatment options for patients with chronic pain.
引用
收藏
页码:1007 / 1022
页数:16
相关论文
共 121 条
[1]   Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? [J].
Albert-Vartanian, A. ;
Boyd, M. R. ;
Hall, A. L. ;
Morgado, S. J. ;
Nguyen, E. ;
Nguyen, V. P. H. ;
Patel, S. P. ;
Russo, L. J. ;
Shao, A. J. ;
Raffa, R. B. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (04) :371-382
[2]  
[Anonymous], 2012, Guidance for Industry Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products
[3]   HIGH-INTENSITY ZONE - A DIAGNOSTIC SIGN OF PAINFUL LUMBAR-DISK ON MAGNETIC-RESONANCE-IMAGING [J].
APRILL, C ;
BOGDUK, N .
BRITISH JOURNAL OF RADIOLOGY, 1992, 65 (773) :361-369
[4]   Depression and pain comorbidity - A literature review [J].
Bair, MJ ;
Robinson, RL ;
Katon, W ;
Kroenke, K .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (20) :2433-2445
[5]   Abuse-Deterrent Opioid Formulations - Putting the Potential Benefits into Perspective [J].
Becker, William C. ;
Fiellin, David A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22) :2103-2105
[6]   The DIRE Score: Predicting outcomes of opioid prescribing for chronic pain [J].
Belgrade, Miles J. ;
Schamber, Cassandra D. ;
Lindgren, Bruce R. .
JOURNAL OF PAIN, 2006, 7 (09) :671-681
[7]   Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials [J].
Bhala, N. ;
Emberson, J. ;
Merhi, A. ;
Abramson, S. ;
Arber, N. ;
Baron, J. A. ;
Bombardier, C. ;
Cannon, C. ;
Farkouh, M. E. ;
FitzGerald, G. A. ;
Goss, P. ;
Halls, H. ;
Hawk, E. ;
Hawkey, C. ;
Hennekens, C. ;
Hochberg, M. ;
Holland, L. E. ;
Kearney, P. M. ;
Laine, L. ;
Lanas, A. ;
Lance, P. ;
Laupacis, A. ;
Oates, J. ;
Patrono, C. ;
Schnitzer, T. J. ;
Solomon, S. ;
Tugwell, P. ;
Wilson, K. ;
Wittes, J. ;
Baigent, C. ;
Adelowo, O. ;
Aisen, P. ;
Al-Quorain, A. ;
Altman, R. ;
Bakris, G. ;
Baumgartner, H. ;
Bresee, C. ;
Carducci, M. ;
Chang, D-M. ;
Chou, C-T. ;
Clegg, D. ;
Cudkowicz, M. ;
Doody, L. ;
El Miedany, Y. ;
Falandry, C. ;
Farley, J. ;
Ford, L. ;
GarciLosa, M. ;
Gonzalez-Ortiz, M. ;
Haghighi, M. .
LANCET, 2013, 382 (9894) :769-779
[8]   ABNORMAL MAGNETIC-RESONANCE SCANS OF THE LUMBAR SPINE IN ASYMPTOMATIC SUBJECTS - A PROSPECTIVE INVESTIGATION [J].
BODEN, SD ;
DAVIS, DO ;
DINA, TS ;
PATRONAS, NJ ;
WIESEL, SW .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1990, 72A (03) :403-408
[9]   μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence [J].
Bohn, LM ;
Gainetdinov, RR ;
Lin, FT ;
Lefkowitz, RJ ;
Caron, MG .
NATURE, 2000, 408 (6813) :720-723
[10]   Enhanced morphine analgesia in mice lacking β-arrestin 2 [J].
Bohn, LM ;
Lefkowitz, RJ ;
Gainetdinov, RR ;
Peppel, K ;
Caron, MG ;
Lin, FT .
SCIENCE, 1999, 286 (5449) :2495-2498